Article

Signature phaco machine offers good stability

Anterior chamber fluctuations during phacoemulsification can cause an increase in retinal thickness and alterations of the blood aqueous barrier. In order to avoid these complications, it is better to use a machine that offers good anterior chamber stability.

Anterior chamber fluctuations during phacoemulsification can cause an increase in retinal thickness and alterations of the blood aqueous barrier. In order to avoid these complications, it is better to use a machine that offers good anterior chamber stability, according to Alessandro Franchini and colleagues from the University of Florence, Italy.

The researchers used a micro silicon sensor interfaced with a control unit, inserted in the anterior chamber during phacoemulsification to continuously monitor the anterior chamber tension in three groups of 20 patients being operated on with three different phacoemulsifiers: Sovereign WhiteStar (AMO), Signature (AMO) and Legacy Everest (Alcon).

The average anterior chamber variation during phacoemulsification was 7.2 mmHg using the Signature, 15.5 mmHg with the WhiteStar and 16.3 mmHg using the Legacy (Signature vs WhiteStar: p<0.05; Signature vs Legacy: p<0.001; WhiteStar vs Legacy: p=0.132).

Anterior fluctuations can cause complications so it is best to use a machine that can guarantee anterior chamber stability. With this in mind the authors recommend using AMOs Signature system to control fluidics thus reducing fluctuations.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.